A method for evaluating treatment switching criteria in multiple sclerosis

Abstract

Background and Objective: We investigated a method to evaluate a treatment switching approach, namely treatment change after one multiple sclerosis (MS) relapse.

Methods: Patients who experienced a relapse while on a first-line disease-modifying therapy, glatiramer acetate, were identified. Based on their subsequent course, patients were divided into two groups: those who changed treatment and those who did not. Patients were allowed to change to any other treatment. Subsequent annualized relapse rate and time to next relapse were compared in the two groups. Since patients were not randomized to treatment group, negative binomial and Cox regression models were used to control for several potential clinical confounders, including relapse severity, relapse duration, age, disease duration and presence of previous/combination therapy. In addition, an inverse probability of treatment weighting model was used to control for confounding. Several secondary analyses investigated patient subgroups.

Results: Statistical modeling showed that there was no significant difference between groups in terms of relapse rate (rate ratio; 95% CI = 0.68; 0.35, 1.31) and time to next relapse (hazard ratio; 95% CI = 0.61; 0.30, 1.25). All secondary analyses confirmed these results. In addition, no significant difference in time to sustained progression on the Expanded Disability Status Scale was observed (p > 0.05). Our approach allowed investigation of the choice to change treatment after a relapse. Conclusions: Our results showed that a single relapse may not be sufficient to indicate treatment failure. Although clinical confounders were addressed in our modeling, unmeasured confounders, particularly the presence of magnetic resonance imaging activity, may have biased our conclusion.

Keywords

disease-modifying therapies multiple sclerosis outcome measurement relapsing—remitting treatment switching

Get full access to this article

View all access options for this article.

References

The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.

Johnson KP , Brooks BR , Cohen JA , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-1276.

Jacobs LD , Cookfair DL , Rudick RA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.

Cohen BA , Khan O. , Jeffery DR , et al. Identifying and treating patients with suboptimal responses . Neurology 2004; 63(12 Suppl 6): S33-40.

Freedman MS , Cohen B. , Dhib-Jalbut S. , et al. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin 2009; 25: 2459-2470.

Gauthier SA , Glanz BI , Mandel M. , et al. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. J Neurol Sci 2009; 284: 116-119.

Carra A. , Onaha P. , Luetic G. , et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina . Eur J Neurol 2008; 15: 386-393.

Caon C. , Din M. , Ching W. , Tselis A. , Lisak R. and Khan O. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2006; 13: 471-474.

Zwibel HL Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurol Scand 2006; 113: 378-386.

10.

Gajofatto A. , Bacchetti P. , Grimes B. , High A. and Waubant E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing- remitting multiple sclerosis . Mult Scler 2009; 15: 50-58.

11.

Gorman MP , Healy BC , Polgar-Turcsanyi M. and Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009; 66: 54-59.

12.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.

13.

Hernan MA and Robins JM Estimating causal effects from epidemiological data. J Epidemiol Community Health 2006; 60: 578-586.

14.

Cox DR and Oakes D. Analysis of survival data. London, New York: Chapman and Hall, 1984.

15.

Lunceford JK and Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004; 23: 2937-2960.

16.

Hernan MA , Brumback B. and Robins JM Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11: 561-570.

17.

Efron B. and Tibshirani R. An Introduction to the Bootstrap. New York: Chapman & Hall, 1993.

18.

Kurth T. , Walker AM , Glynn RJ , et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006; 163: 262-270.

19.

Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria : R Foundation for Statistical Computing, 2009.

20.

Venables WN and Ripley BD Modern Applied Statistics with S, 4th edn. New York: Springer, 2002.

21.

Therneau T. and Lumley T. survival: Survival analysis, including penalised likelihood. R package version 2.35-7. 2009. http://CRAN.R-project.org/package=survival.

22.

Trojano M.

Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?

Neurology 2007; 69: 1478-1479.

23.

Bang H. and Robins JM Doubly robust estimation in missing data and causal inference models. Biometrics 2005; 61: 962-973.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.05 MB